KNSA

SEC source: 0001415889-25-012541 · form4-05092025_090502.xml · nonDerivative · entry 2

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,403

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

SEC source: 0001415889-25-012541 · form4-05092025_090502.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,603

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 8

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,621

Underlying: Class A Ordinary Share · 1,965 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,674

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.03 and $27.14. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 7

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,040

Underlying: Class A Ordinary Share · 14,420 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 6

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,002

Underlying: Class A Ordinary Share · 2,998 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

F2 · derivative.expiration_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 5

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 229 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

F2 · derivative.expiration_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 4

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,546

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 3

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,193

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 2

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,775

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 10

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,389

Underlying: Class A Ordinary Share · 6,272 shares

Expires 2033-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F10 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 4

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,415

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 3

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 9

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,661

Underlying: Class A Ordinary Share · 3,850 shares

Expires 2033-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F10 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 2

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,415

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · nonDerivative · entry 1

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

SEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 13

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,909

Underlying: Class A Ordinary Share · 13,141 shares

Expires 2033-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-25-011690 · form4-05012025_100529.xml · derivative · entry 12

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Share · 12,000 shares

Expires 2029-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 8

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,009

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 7

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-25-011690 · form4-05012025_100529.xml · nonDerivative · entry 6

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 18

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,511

Underlying: Class A Ordinary Share · 1,157 shares

Expires 2033-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F9 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 17

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,059

Underlying: Class A Ordinary Share · 8,671 shares

Expires 2032-04-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F8 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · derivative · entry 16

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,594

Underlying: Class A Ordinary Share · 13,406 shares

Expires 2029-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 10

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,415

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.11. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 9

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 8

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

SEC source: 0001415889-25-011692 · form4-05012025_100513.xml · nonDerivative · entry 7

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

SEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 4

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,606

Underlying: Class A Ordinary Share · 7,606 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,368

Underlying: Class A Ordinary Share · 7,368 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 2

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,876

Underlying: Class A Ordinary Share · 4,786 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011981 · form4-05052025_080539.xml · derivative · entry 1

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,558

Underlying: Class A Ordinary Share · 4,558 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 8

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,303

Underlying: Class A Ordinary Share · 8,303 shares

Expires 2035-04-30

F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F9 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 7

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,043

Underlying: Class A Ordinary Share · 8,043 shares

Expires 2035-04-30

F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F8 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 6

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,225

Underlying: Class A Ordinary Share · 5,225 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F7 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F7 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011992 · form4-05052025_080547.xml · derivative · entry 5

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,976

Underlying: Class A Ordinary Share · 4,976 shares

Expires not disclosed

F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F5 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F6 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

F6 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011988 · form4-05052025_080511.xml · derivative · entry 4

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,302

Underlying: Class A Ordinary Share · 8,302 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011988 · form4-05052025_080511.xml · derivative · entry 3

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,042

Underlying: Class A Ordinary Share · 8,042 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011988 · form4-05052025_080511.xml · derivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,224

Underlying: Class A Ordinary Share · 5,224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011988 · form4-05052025_080511.xml · derivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,975

Underlying: Class A Ordinary Share · 4,975 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,238

Underlying: Class A Ordinary Share · 13,328 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 3

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,910

Underlying: Class A Ordinary Share · 12,910 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,386

Underlying: Class A Ordinary Share · 8,386 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011979 · form4-05052025_080509.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,987

Underlying: Class A Ordinary Share · 7,987 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 4

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,456

Underlying: Class A Ordinary Share · 5,456 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 3

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,285

Underlying: Class A Ordinary Share · 5,285 shares

Expires 2035-04-30

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

SEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 2

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,433

Underlying: Class A Ordinary Share · 3,433 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

SEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,270

Underlying: Class A Ordinary Share · 3,270 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.